Rheumatology International

, Volume 33, Issue 6, pp 1379–1386

Maximizing early treatment with biologics in patients with rheumatoid arthritis: the ultimate breakthrough in joints preservation


DOI: 10.1007/s00296-012-2629-4

Cite this article as:
Balanescu, A. & Wiland, P. Rheumatol Int (2013) 33: 1379. doi:10.1007/s00296-012-2629-4


Rheumatoid arthritis (RA) is a chronic, systemic, progressive inflammatory disease that, if left untreated, can lead to irreversible joint damage and serious disability. In Central and Eastern Europe, RA treatment varies widely, partly due to economic factors, restrictive treatment guidelines, and access to practicing rheumatologists. The recent treatment paradigm shift of treating to target in RA with early, aggressive therapy has proven to be a successful strategy for achieving optimal clinical outcomes. Several clinical studies demonstrate that utilizing this strategy with anti-tumor necrosis factor biologics leads to improved clinical, radiographic, and functional outcomes. Patient education is also a critical component of the treating to target strategy, and the patient’s version of the treat-to-target recommendations is an important tool for successful implementation. This review discusses the evidence for the treat-to-target approach and describes areas to improve the disparity of treatment between patients in Western European compared with Central and Eastern European countries.


Rheumatoid arthritisPatient care managementEarly diagnosisTreatment outcomeEastern EuropeReview

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of Rheumatology and Internal Medicine, “Sf. Maria” HospitalUniversity of Medicine and Pharmacy “Carol Davila”BucharestRomania
  2. 2.Chair, Clinic of Rheumatology and Internal DiseasesSilesian Piasts University of MedicineWroclawPoland